FDA’s Florence Houn Joins Celgene Regulatory Affairs Department
Executive Summary
Celgene has tapped FDA's Florence Houn as VP-regulatory policy and strategy at a time when the company is working to comply with the Risk Evaluation and Mitigation Strategies provisions of the FDA Amendments Act
You may also be interested in...
Can A REMS Block A Generic? Thalomid Could Be Early Test
Celgene's arguments against generics of Thalomid (thalidomide) offer another example of the potentially vast consequences of FDA's new safety powers: The firm is arguing that the complexity of its risk management plan precludes the approval of alternate versions of the product
Galson Backed Initial Plan B Denial In Fear His Job Was In Jeopardy – Jenkins
Center for Drug Evaluation & Research Director Steven Galson initially signed off on the "not approvable" letter for Barr's emergency contraceptive Plan B OTC switch in fear that he would lose his job, according to testimony by senior CDER officials
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.